Hmm..
"
On 28 October 2013, Invion announced it had entered a licence agreement with Accolade Pharma LLC for an exclusive, worldwide licence to develop and commercialise all inhaled formulations and applications of zafirlukast. A licence fee of $500,000 was payable by Invion to Accolade Pharma LLC over a 12 month period commencing January 2014. Dr Mitchell Glass, Invion’s Executive Vice President of R&D and Chief Medical Officer, led the development and submission of Accolate for Zeneca (now AstraZeneca) to its FDA approval letter in 1998, and is a substantial shareholder of Accolade Pharma LLC. "
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.015(12.0%) |
Mkt cap ! $9.320M | |||
| Open | High | Low | Value | Volume |
| 12.0¢ | 12.5¢ | 10.5¢ | $24.18K | 211.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 30000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 28316 | 1 |
View Market Depth
| Last trade - 15.59pm 25/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |